News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,193 Results
Type
Article (13819)
Company Profile (101)
Press Release (252273)
Multimedia
Podcasts (47)
Webinars (10)
Section
Business (88075)
Career Advice (465)
Deals (15345)
Drug Delivery (67)
Drug Development (36607)
Employer Resources (49)
FDA (6301)
Job Trends (6202)
News (150268)
Policy (14047)
Tag
Academia (441)
Accelerated approval (2)
Adcomms (6)
Allergies (36)
Alliances (23243)
ALS (37)
Alzheimer's disease (394)
Antibody-drug conjugate (ADC) (43)
Approvals (6340)
Artificial intelligence (113)
Autoimmune disease (9)
Automation (4)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (57)
Biotechnology (40)
Bladder cancer (22)
Brain cancer (16)
Breast cancer (83)
Cancer (647)
Cardiovascular disease (73)
Career advice (409)
Career pathing (12)
CAR-T (23)
Cell therapy (90)
Cervical cancer (4)
Clinical research (30953)
Collaboration (354)
Compensation (165)
Complete response letters (17)
COVID-19 (760)
CRISPR (22)
C-suite (130)
Cystic fibrosis (37)
Data (675)
Denatured (15)
Depression (10)
Diabetes (83)
Diagnostics (1326)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (61)
Drug pricing (66)
Drug shortages (12)
Duchenne muscular dystrophy (37)
Earnings (32257)
Editorial (12)
Employer branding (4)
Employer resources (43)
Events (37629)
Executive appointments (403)
FDA (6748)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (218)
Gene editing (40)
Generative AI (9)
Gene therapy (102)
GLP-1 (350)
Government (1301)
Grass and pollen (3)
Guidances (27)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (12)
Immunology and inflammation (36)
Indications (14)
Infectious disease (795)
Inflammatory bowel disease (57)
Inflation Reduction Act (6)
Influenza (14)
Intellectual property (48)
Interviews (59)
IPO (5882)
IRA (29)
Job creations (2051)
Job search strategy (373)
Kidney cancer (6)
Labor market (12)
Layoffs (181)
Leadership (4)
Legal (3433)
Liver cancer (19)
Lung cancer (87)
Lymphoma (57)
Machine learning (2)
Management (16)
Manufacturing (164)
MASH (34)
Medical device (1278)
Medtech (1280)
Mergers & acquisitions (9676)
Metabolic disorders (267)
Multiple sclerosis (21)
NASH (14)
Neurodegenerative disease (24)
Neuropsychiatric disorders (8)
Neuroscience (584)
NextGen: Class of 2025 (1586)
Non-profit (595)
Now hiring (8)
Obesity (152)
Opinion (119)
Ovarian cancer (22)
Pain (55)
Pancreatic cancer (15)
Parkinson's disease (47)
Partnered (7)
Patents (124)
Patient recruitment (30)
Peanut (10)
People (28998)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8057)
Phase II (13095)
Phase III (11751)
Pipeline (480)
Policy (72)
Postmarket research (1401)
Preclinical (3235)
Press Release (25)
Prostate cancer (49)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (170)
Real estate (2638)
Recruiting (17)
Regulatory (10147)
Reports (14)
Research institute (566)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (8)
Schizophrenia (37)
Series A (38)
Series B (14)
Service/supplier (3)
Sickle cell disease (32)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1629)
State (2)
Stomach cancer (3)
Supply chain (32)
Tariffs (32)
The Weekly (30)
Vaccines (158)
Venture capitalists (14)
Weight loss (100)
Women's health (8)
Worklife (4)
Date
Today (71)
Last 7 days (292)
Last 30 days (914)
Last 365 days (11752)
2025 (4010)
2024 (12503)
2023 (14248)
2022 (19558)
2021 (20070)
2020 (19033)
2019 (14885)
2018 (11713)
2017 (13891)
2016 (13130)
2015 (15497)
2014 (12423)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (57)
Arkansas (3)
Asia (20184)
Australia (2616)
California (1800)
Canada (940)
China (251)
Colorado (71)
Connecticut (71)
Delaware (62)
Europe (39540)
Florida (342)
Georgia (39)
Idaho (9)
Illinois (205)
India (16)
Indiana (138)
Iowa (1)
Japan (98)
Kansas (58)
Kentucky (13)
Louisiana (1)
Maine (2)
Maryland (266)
Massachusetts (1551)
Michigan (30)
Minnesota (97)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (9)
New Hampshire (6)
New Jersey (794)
New Mexico (7)
New York (540)
North Carolina (405)
North Dakota (2)
Northern California (741)
Ohio (51)
Oklahoma (4)
Oregon (16)
Pennsylvania (463)
Puerto Rico (8)
Rhode Island (10)
South America (502)
South Carolina (2)
Southern California (757)
Tennessee (35)
Texas (239)
United States (7527)
Utah (36)
Virginia (79)
Washington D.C. (32)
Washington State (124)
Wisconsin (17)
266,193 Results for "yamo pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79 to Treat the Core Symptoms of Autism Spectrum Disorder
Yamo Pharmaceuticals LLC, a clinical stage pharmaceutical company, announced that it has completed enrollment in its Phase 2 study evaluating L1-79 in adolescents and young adults with autism spectrum disorder.
November 20, 2023
·
5 min read
Press Releases
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
July 30, 2024
·
4 min read
Drug Development
As Autism Cases Rise, Biopharma Springs Into Action
Several companies—including Roche, Curemark and Yamo Pharmaceuticals—are running clinical trials of treatments that aim to offset the myriad challenges of autism.
April 25, 2024
·
6 min read
·
Tyler Patchen
Business
Yamo Pharmaceuticals Receives Investment from Autism Impact Fund to Support Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals, LLC announced that The Autism Impact Fund has made a capital investment in Yamo to support a Phase 2 study of L1-79 in adolescents and adults with ASD.
November 10, 2021
·
3 min read
Drug Development
Yamo Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study of L1-79 in Autism Spectrum Disorder
Yamo Pharmaceuticals today announced that the first patient has been treated in a Phase 2 study of L1-79 in adolescents and young adults with ASD at six U.S. research centers of excellence.
January 27, 2022
·
4 min read
Drug Development
Trust, Tech, and Tomorrow: A Pharmaceutical Executive’s WEF Insights
Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the World Economic Forum to SCOPE 2025.
March 5, 2025
·
1 min read
·
Lori Ellis
Mergers & acquisitions
Taiho Pharmaceutical Buys ADC Partner Araris for up to $1.1B Total
Japan-based Taiho Pharmaceutical has worked with Araris Biotech since 2023 developing antibody-drug conjugates for the oncology space.
March 17, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
X4 Pharmaceuticals Announces Reverse Stock Split
April 24, 2025
·
6 min read
Press Releases
Autism Spectrum Disorder Markets Expected to Exhibit a CAGR Of 5.84% During 2025-2035, impelled by Innovative Treatments
February 13, 2025
·
10 min read
Press Releases
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
April 8, 2025
·
4 min read
1 of 26,620
Next
